Updated Jul 16, 2026
Davis Todd C has filed 3 SEC Form 4 filings across 3 companies in the last 90 days — buying. Lifetime open-market purchases: $1000K.
Todd C. Davis is an executive involved in the biotechnology sector, currently serving as the Chief Executive Officer and Director at Pelthos Therapeutics Inc. He has also held roles at Palvella Therapeutics, Inc. and Ligand Pharmaceuticals Inc.
| Role | Chief Executive Officer, Director |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-06 | LGND | LIGAND PHARMACEUTICALS INC | J — Other acquisition / disposition | 132 | $160.71 | $21K |
| 2026-06-15 | PTHS | Pelthos Therapeutics Inc. | P — Open-market purchase | 503 | $28.73 | $14K |
| 2026-06-15 | PTHS | Pelthos Therapeutics Inc. | P — Open-market purchase | 35.4K | $27.80 | $986K |
| 2026-04-01 | PTHS | Pelthos Therapeutics Inc. | A — Grant or award | 19.1K | $0.00 | |
| 2026-04-01 | PTHS | Pelthos Therapeutics Inc. | A — Grant or award | 5.0K | $0.00 | |
| 2026-04-01 | PTHS | Pelthos Therapeutics Inc. | A — Grant or award | 12.9K | $0.00 | |
| 2026-03-28 | LGND | LIGAND PHARMACEUTICALS INC | A — Grant or award | 10.5K | $0.00 | |
| 2026-02-18 | LGND | LIGAND PHARMACEUTICALS INC | F — Tax withholding / forfeiture | 2.8K | $183.83 | $516K |
| 2026-02-18 | LGND | LIGAND PHARMACEUTICALS INC | F — Tax withholding / forfeiture | 4.3K | $183.83 | $782K |
| 2026-02-18 | LGND | LIGAND PHARMACEUTICALS INC | F — Tax withholding / forfeiture | 2.0K | $183.83 | $375K |
| 2026-02-18 | LGND | LIGAND PHARMACEUTICALS INC | F — Tax withholding / forfeiture | 15.6K | $183.83 | $2.87M |
| 2026-02-18 | LGND | LIGAND PHARMACEUTICALS INC | A — Grant or award | 39.6K | $0.00 | |
| 2026-02-18 | LGND | LIGAND PHARMACEUTICALS INC | F — Tax withholding / forfeiture | 8.2K | $183.83 | $1.50M |
| 2026-02-18 | LGND | LIGAND PHARMACEUTICALS INC | A — Grant or award | 20.8K | $0.00 | |
| 2025-07-01 | PTHS | Pelthos Therapeutics Inc. | J — Other acquisition / disposition | 1.50M | $10.00 | $15.00M |
| 2025-06-30 | LGND | LIGAND PHARMACEUTICALS INC | J — Other acquisition / disposition | 233 | $91.08 | $21K |
Todd C. Davis is an executive involved in the biotechnology sector, currently serving as the Chief Executive Officer and Director at Pelthos Therapeutics Inc. He has also held roles at Palvella Therapeutics, Inc. and Ligand Pharmaceuticals Inc.…
3 primary Form 4 filings in the last 90 days, covering 3 companies.
Recorded transactions: 2 open-market purchases ($1000K) and 0 open-market sales () across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Davis Todd C profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.